Lilly has been solidly investing in research and development (R&D) throughout 2024. In April, the company announced the ...

Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly (LLY) has partnered with the government of the United Kingdom to see if its blockbuster weight loss drug could help ...

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...

Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...

IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 4.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and ...

In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating yesterday. Nico Chen has given his Buy rating due ...

Eli Lilly is expanding its innovation digs to Beijing, opening two research centers called the Eli Lilly China Medical ...